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Abstract Alterations in peripheral and central indices of
serotonin (5-hydroxytryptamine, 5-HT) production, storage
and signaling have long been associated with autism. The
5-HT transporter gene (HTT, SERT, SLC6A4) has received
considerable attention as a potential risk locus for autism-
spectrum disorders, as well as disorders with overlapping
symptoms, including obsessive-compulsive disorder
(OCD). Here, we review our efforts to characterize rare,
nonsynonymous polymorphisms in SERT derived from
multiplex pedigrees carrying diagnoses of autism and OCD
and present the initial stages of our effort to model one of
these variants, Gly56Ala, in vivo. We generated a targeting
vector to produce the Gly56Ala substitution in the Slc6a4
locus by homologous recombination. Following removal of
a neomycin resistance selection cassette, animals exhibiting
germline transmission of the Ala56 variant were bred to
establish a breeding colony on a 129S6 background,
suitable for initial evaluation of biochemical, physiological
and behavioral alterations relative to SERT Gly56 (wild-
type) animals. SERT Ala56 mice were achieved and exhibit
a normal pattern of transmission. The initial growth and
gross morphology of these animals is comparable to
wildtype littermate controls. The SERT Ala56 variant can
be propagated in 129S6 mice without apparent disruption
of fertility and growth. We discuss both the opportunities
and challenges that await the physiological/behavioral
analysis of Gly56Ala transgenic mice, with particular
reference to modeling autism-associated traits.
Keywords Serotonin.Transporter.Polymorphism.
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Introduction
The serotonin system is implicated in autism
Elevated whole blood serotonin (5-hydroxytryptamine, 5-
HT) was first reported in autism by the lab of Daniel X.
Freedman in 1961 [1], well before 5-HT was fully accepted
as a neurotransmitter [2]. Serotonin was discovered as a
serum factor leading to vasoconstriction in 1948 by
Maurice Rapport and colleagues [3]. This work converged
with that of Vittorio Erspaner, who identified in 1952 that
5-HT was the agent secreted by enterochromaffin cells
previously designated as ‘enteramine’ [4]. Subsequent work
demonstrated that 5-HT synthesized in enterochromaffin
cells is released into the enteric circulation and taken up by
platelets, which contain more than 99% of the 5-HT in
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e-mail: randy.blakely@vanderbilt.eduperipheral blood [5]. Due to the vastly greater amount of 5-
HT contained in platelets, it is challenging to measure free
5-HT in plasma, and it is unclear if plasma 5-HT levels are
changed in autism [6, 7]. Thus, hyperserotonemia appears
to arise from elevated platelet stores of 5-HT.
Nearly fifty years have passed since the initial description
of whole blood 5-HT as a biomarker in autism, described
sixteen years earlier by Leo Kanner [8]. Subsequent studies
have repeatedly demonstrated that more than one-quarter of
autistic children are found to have elevated whole blood 5-
HT levels [9], and, indeed, hyperserotonemia is arguably
the most highly reproduced biomarker linked to a neuro-
behavioral disorder. A recent study in a more homogeneous
Dutch population suggests that whole blood 5-HT may
actually show a bimodal distribution in autism [10]. Despite
the long-standing observation of hyperserotonemia in
autism, our understanding of its origin and relationship to
the etiology of autism remains incomplete.
Functional studies of the platelet serotonin system in
autism have evaluated both the serotonin transporter and
serotonin receptors. The 5-HT transporter (5HTT, SERT)
is essential for the uptake of the biogenic amine into the
platelet. Some but not all studies indicate alterations in
platelet 5-HT uptake as well as SERT binding levels in
autism [11–19]. Some studies have also shown decreased
platelet serotonin receptor 5-HT2 binding [20–22], which
could possibly influence platelet 5-HT levels by modula-
tion of platelet activation and release. Of note, recent work
from our laboratory indicates that the 5-HT2A receptor can
modulate SERT associations with the platelet membrane
skeleton [23]. Inconsistency in transporter and receptor
studies in autism likely reflects the complex regulatory
systems that control platelet 5-HT utilization as well as
platelet activation. Certainly, an important consideration
is the regulation of gut production of 5-HT and its
regulation by intrinsic signaling and transport mecha-
nisms [24–28].
The robustness of hyperserotonemia as an autism
biomarker has helped focus research on the genetic control
of platelet 5-HT levels, with the belief that common
regulatory mechanisms in the platelet and the central
nervous system could reveal genes important to autism
susceptibility. Indeed, one small study found higher whole
blood 5-HT levels in children with ASD who had an
affected sibling than in children with ASD but no affected
siblings [29]. In the Hutterites, a large founder population
not ascertained for brain disorders, whole blood 5-HT
levels were found to be under nearly complete genetic
control, with a heritability of 0.99 [30]. In a small twin
study, the maximum rate of 5-HT uptake was also found to
be highly heritable [31]. The Cook lab has used linkage
and association to map quantitative trait loci for whole
blood 5-HT levels in the Hutterites [32]. The initial study
found significant association at a functional polymorphism
in the integrin β3 subunit gene (ITGB3)a sw e l la s
suggestive association at the Vitamin D receptor gene
[32]. Follow-up analyses revealed that ITGB3,a sw e l la s
the 5-HT transporter gene (SLC6A4), were primarily
associated with whole blood 5-HT levels in males [33].
Carneiro and colleagues subsequently demonstrated phys-
ical and functional interactions between the ITGB3 and
SERT proteins that regulates both platelet 5-HT uptake
and aggregation [26]. Consistent with these findings, three
studies have now reported a gene-gene interaction be-
tween ITGB3 and SLC6A4 in association with autism [34–
36], supporting the idea that whole blood 5-HT represents
a genetically-determined, intermediate phenotype in au-
tism that can be mined for elucidation of disease
susceptibility genes.
Recent data support the idea that the 5-HT system is also
altered in the brain in autism. If the peripheral findings
translate into the brain, increased 5-HT uptake or storage in
the presynaptic terminal would be expected to diminish
extracellular 5-HT availability. Unfortunately, a direct
assessment of synaptic 5-HT in patients with autism is not
possible with present technologies. A surrogate measure is
the assessment of brain 5-HT synthesis, and indeed this
measure demonstrates an altered developmental pattern in
autism [37]. Other studies have evaluated 5-HT receptor
binding. Two neuroimaging studies have found decreased
5-HT2 receptor binding, one a SPECT study in adults with
Asperger’s syndrome [38] and the second a PET study in
parents of children with autism [39]. Blatt’s group has also
presented data demonstrating decreased 5-HT2A binding in
post-mortem samples from autism subjects [40]. The
overall consistent findings of decreased 5-HT2 receptor
binding in platelet, neuroimaging, and post-mortem studies
supports the hypothesis that peripheral alterations in 5-HT
systems contribute to the behavioral abnormalities associ-
ated with autism.
Finally, limited pharmacology studies underscore a role
for the 5-HT system in autism. Dietary depletion of the 5-
HT precursor tryptophan, which is expected to cause
decreased synaptic 5-HT, leads to worsened repetitive
behaviors and irritability in autism [41]. Consistent with
these findings, several studies have reported that 5-HT
reuptake inhibitors can relieve symptoms of irritability and
rigid-compulsive behavior in autism [42, 43]; more recent
data from clinical trials are less supportive, but the wide
spectrum of autism traits complicates selection of appro-
priate target symptoms in these trials. More consistent
data supports the use of risperidone [44, 45], an atypical
antipsychotic with antagonism at multiple monoamine
receptors, including the 5-HT2A receptor. It is striking that
this agent has clinical utility in autism despite findings of
reductions in 5-HT2A receptor levels. This discrepancy
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5-HT2A receptor sensitivity in these subjects may exist
which may then trigger compensatory receptor down-
regulation.
Rare variants offer one way to approach complexity
at the SERT gene
Multiple lines of evidence favor involvement of the 5-HT
transporter gene (SLC6A4) in autism; although the cumu-
lative data are not straightforward or uniform in their
support, which is perhaps not surprising in a complex
behavioral disorder with a polygenic origin. Most of this
evidence has emerged from candidate gene studies oriented
around the platelet 5-HT system. Importantly, linkage
studies have also implicated the chromosome 17q11-q21
region containing SLC6A4 [46, 47]. Follow-up linkage
studies [48–50] have detected more significant evidence for
linkage in this region when considering families with two
or more affected male children and no affected females.
These findings suggest that SERT might harbor sex-specific
risk alleles for autism and possibly contribute to, or be
responsive to, the gender bias of autism. Such an idea is in
line with the findings that variation in SLC6A4 is primarily
associated with whole blood 5-HT levels in males [33]. It
also matches accumulating evidence in the 5-HT transporter
knockout mouse that altered expression of SLC6A4 has
sexually dimorphic effects on brain 5-HT systems and
resulting behavior (reviewed in [51]).
With the accumulated evidence of alterations in the
platelet 5-HT system in autism, it is not surprising that
some of the earliest candidate gene association studies in
autism focused on the SERT gene. Unfortunately, studies of
SLC6A4 in autism have been complicated by the presence
of multiple common functional variants in gene regulatory
regions. The best-studied of these variants, the promoter
length polymorphic repeat (5-HTTLPR) [52], was initially
reported as associated with autism in haplotype analyses by
the Cook lab [53]. Subsequent studies have yielded
inconsistent findings. Indeed, although most studies have
reported association with the short allele, which leads to
less gene transcription, others have reported association
with the long allele (reviewed in a recent meta-analysis
[54]). Genotyping errors could possibly account for some
of this inconsistency given deviation from Hardy-Weinberg
equilibrium in some samples and discrepancies in geno-
types of the same samples across different laboratories [55].
Other studies have explored the possible involvement of
SLC6A4 in autism by expanding the range of polymorphisms
studied. Indeed, multiple, additional functional polymor-
phisms have been discovered within the SLC6A4 gene
regulatory regions [56–58], including a single nucleotide
polymorphism (SNP) that reduces the functional impact of
the 5-HTTLPR long allele (La, Lg) [57]. To date, these
polymorphisms have not been systematically studied in large
autism samples. Other SLC6A4 polymorphisms and haplo-
types that have been reported to associate with autism have
not been fully characterized for either their own functional
significance or linkage disequilibrium with other possible
functional variants [59, 60]. Indeed, one haplotype in linkage
disequilibrium with the 5-HTTLPR short allele, which leads
to decreased SERT expression, has actually been associated
with increased platelet 5-HT uptake [61]. These findings
signify a still incomplete understanding of SERT genetic
regulation. A comprehensive analysis focusing on the impact
of multiple alleles on predicted SERT expression or function
should greatly enhance our understanding of the SERT-
serotonin-autism connection.
Another fruitful approach to understanding the possible
involvement of SLC6A4 in autism susceptibility is to focus
on either specific symptom clusters or on intermediate
phenotypes. Four studies have reported association at
various SLC6A4 polymorphisms when performing sub-
analyses of repetitive behavior in autism [49, 60, 62, 63].
One of these studies also reported association of the 5-
HTTLPR short allele with poor non-verbal communication
[63]. Two studies have reported association of various
SLC6A4 polymorphisms with either whole blood 5-HT [64]
or with 5-HT uptake in autism [61]. Finally, one study
reported association of the 5-HTTLPR short allele with
increased cortical gray matter in two- to four-year-old
children with autism [65]. These collected studies of
subphenotypes or intermediate phenotypes add strength to
the hypothesis that SLC6A4 represents a susceptibility gene
for subgroups of children with autism.
One intriguing possibility to emerge from the data on
common SLC6A4 variants is that optimal SERT activity is
likely to be highly constrained, with both high and low
SERTactivity impacting autism susceptibility, though likely
with different patterns of symptoms and intermediate
phenotypes. Such an idea parallels ideas emerging from
recent findings at the MECP2 gene implicated in Rett
syndrome [66]. Additionally, this idea fits with the
observation that genetic variation can lead to increased
SERT function in association with repetitive behavior in
autism [32, 46], as well as with OCD [56, 57, 67]; whereas
genetic variation that supports decreased SERT function is
associated with impaired social behavior [63] and increased
cortical size in young children with autism [65], as well as
in a mouse model of PTEN-associated autism [68].
Association of human SERT gene variants with autism
traits
Despite intriguing findings of both common and rare
functional SLC6A4 variants, the collective evidence does
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male sibling pairs in this chromosomal region [48–50].
Indeed, the collected evidence suggests that no single,
common functional polymorphism at this locus underlies
autism susceptibility, at least when considered individually.
Recently, the Blakely and Sutcliffe labs explored the
alternative hypothesis that multiple, rare functional variants
account for some of the findings of linkage in this region.
In a comprehensive analysis of SERT noncoding and
coding exons from 120 families that contributed most to
linkage at 17q11.2, our groups found 5 coding substitutions
and 15 variants in 5´ noncoding and intronic regions
transmitted in families [49]. In the aggregate, these variants
showed significant association to autism and tracked
specifically with rigid-compulsive traits.
In the initial study, one of the autism-associated variants,
Gly56Ala, showed constitutively elevated SERT activity
that was not further up-regulated through the PKG and p38
MAPK pathways in transformed lymphoblasts from autism
probands [49]. This polymorphism, at an amino acid that is
conserved across all mammalian SERTs, was the only
SERT variant frequent enough to attempt independent
statistical analyses, which revealed that the Ala56 allele:
1) was overtransmitted 3:1 to subjects with autism (P=
0.025), 2) displayed a gender-bias (males) when consider-
ing affected subjects within linked pedigrees (P=0.017),
and 3) was associated with Autism Diagnostic Interview
component factors corresponding to rigid-compulsive traits
(P=0.0085) and sensory aversion (P=0.0005). The SERT
amino-terminus where Gly56 resides is an important
regulatory area [69–71]. These considerations make the
Gly56Ala allele an important allele to model for system
level effects in an animal model (see below).
Two of the SERT coding variants found in autism
subjects in our studies, Gly56Ala and Lys605Asn, were
both shown to exhibit a gain of function despite normal
surface expression [72]. Our autism studies uncovered three
additional SERT coding variants: Ile425Leu, Phe465Leu
and Leu550Val. All three variants occur within transmem-
brane domains at amino acids that are highly conserved
[49]. Rigid-compulsive behaviors were associated with
these three novel SERT variants when analyzed as a group
(P=0.0003) [49]. When all linked families with individuals
carrying a coding variant were considered together, the
significance in elevated severity of rigid-compulsive behav-
iors increased (P=0.0006).
Even these rare variants are unlikely to present a simple
story given the presence in the SERT gene of multiple
commonfunctionalvariantsthatcanaffectgeneexpression.It
is entirely possible that the functional effects of these rare
variants, particularly the more subtle increased activity and
dysregulation of Gly56Ala, could be partially offset in some
individuals by common variants leading to decreased SERT
expression or variation in other genes within 5-HT signaling
networks. Indeed, one subsequent study did not find
association of rare SERT variants with autism or rigid-
compulsive behavior in families without evidence for linkage
to this region [73]. Another study did not find association of
the Ala56 allele when considered alone in OCD [74];
although it is quite possible that these seemingly related
disorders arise from distinct origins. Regardless, the discov-
ery of functional amino acid variants in SERT offers a
critical opportunity to translate altered SERT activity into an
animal model for comprehensive assessment of genotype/
phenotype assessments beyond what is feasible in humans.
In vitro analysis of autism-associated SERT coding variants
Of the five coding variants that we identified in probands
from multiplex autism families, two of these, Gly56Ala and
Lys605Asn, were actually first characterized, along with
eight other rare SERT variants, independent of their
potential roles in autism [72, 75]. In comparison to the
reference hSERT cDNA (often termed “wild-type”) origi-
nally identified by Ramamoorthy and colleagues [76], both
Ala56 and Asn605 demonstrated elevated 5-HT transport
activity in transfected HeLa cells [72]. This gain-of-
function transport property was shared (and even exceeded)
by several other SERT coding variants including Ile425Val,
a variant reported by Ozaki and colleagues in association
with two pedigrees bearing a complex neuropsychiatric
phenotype including OCD, autism spectrum disorder, social
phobia, and alcohol abuse [77]. Since these studies,
additional cases of Val425 in OCD have been reported
[78]. Clearly, the identification of two mutations at the
same site (Val425 vs Leu425) in disorders with trait overlap
increases the probability that both are functional and
relevant to disease status.
Recently, we described the functional properties of
Leu425, Leu465 and Val550, expressed in HeLa cells in
parallel with Ala56 and wildtype human SERT [79]. These
studies (Fig. 1) revealed for the first time that all autism-
associated SERT coding variants confer a gain-of-function
phenotype. Kinetic studies provided the first evidence,
however, that the elevated SERT activities of these variants
arise from distinct mechanisms. Thus, Ala56 displays a
reduction in 5-HT KM, consistent with a shift to a high-
affinity state for 5-HT, whereas the other three variants
display elevated VMAX and no change in KM (Table 1).
VMAX increases in transport kinetic studies are typically
associated with changes in the number of transporter
molecules expressed at the cell surface, though other
explanations are possible. Interestingly, Kilic and col-
leagues reported that Ile425Val exhibits a KM shift with
no change in VMAX. As we have discussed elsewhere [71],
the Kilic studies utilized an overexpression system (COS
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comparable to that seen in natively expressing cell lines
(e.g. RBL-2H3, RN46A). Possibly, the high expression
levels of the COS overexpression system preclude detection
of Vmax changes whereas a trafficking impact in our HeLa
model might somehow mask KM effects, though they are
detectible for Gly56Ala and Lys605Asn.
In part due to the discrepancies with kinetic analyses
noted above, we performed surface binding and biotinyla-
tion studies on all autism-associated SERT variants [79].
These studies reveal that all variants exhibit comparable
total [
125I]RTI-55 binding, compatible with evidence of
equivalent protein expression as detected by Western blots
(Fig. 2). In contrast, differences in [
125I]RTI-55 surface
expression were evident between Gly56Ala and the other
SERT coding variants, findings verified in surface protein
biotinylation studies. Whereas surface Gly56Ala levels were
equivalent to, or lower than that found for wildtype SERT,
surface expression of Leu425, Leu465 and Val550 were
significantly elevated. Thesedataindicate that theincrease in
uptake activity for Ala56 in transiently-transfected HeLa
cells comes about from catalytic activation, whereas the
increases in uptake for Leu425, Leu465 and Val550 arise
from enhanced surface expression. Whether the latter effects
arise from elevated insertion of transporters, reduced
endocytosis or enhanced recycling after endocytosis is not
known but presently under evaluation.
A striking feature of the Ala56 variant (and Asn605)
observed in our initial characterization of deposited SERT
variants [72] is its lack of responsiveness to two protein
kinases previously shown to influence SERT surface
expression [80] (protein kinase G, PKG) and catalytic
activation [80] (p38 mitogen activated protein kinase, p38
MAPK). These observations compelled us to evaluate all
autism-associated SERT coding variants for their ability to
support acute regulation by these kinases. As before, Ala56
was insensitive to activators of either PKG or p38 MAPK
(Fig. 3). In contrast, stimulation of these kinases produced
significant increases in activity for Leu425, Leu465 and
Val550, though slightly lower than that observed for
wildtype SERT. Regardless, these observations support the
presence of two distinct classes of functional perturbations
for these variants. Similar distinctions were also evident
with protein kinase C regulation, where enhanced sensitiv-
ity is evident for Ala56 but not for Leu425, Leu465 and
Val550. The Ser/Thr protein phosphatase 2A (PP2A) has
been implicated in SERT regulation and forms a reversible
physical complex with the transporter [81]. Although PKC,
PKG and p38 MAPK activators distinguish among SERT
variants, PP2A antagonist sensitivity appears to be lost for
both Ala56 and Leu425, two variants that represent the two
distinct classes of regulatory defects observed in SERT
variants. These findings indicate that altered PP2A inter-
actions or SERT dephosphorylation may be a more
fundamental alteration that extends across all variants, with
secondary effects linked to the physical site of mutations.
Additional studies are needed to localize the site(s) of
interaction of PP2Awith SERT, as well as the sites of SERT
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Fig. 1 Location and 5-HT transport activity of autism-associated
SERT coding variants. A) Autism-associated variants are overlayed on
a 12 TM model of a single SERT subunit, with NH2 and COOH
termini oriented inside the cell. Variants in extramembrane domains
are shaded black whereas those in membrane domains are shaded
white. B) Altered activity of SERT variants is evident in native
lymphocytes. Lymphocytes were genotyped and cultured and assessed
for 5-HT uptake. Data presented derive from n=3 individual assays on
lymphocyte lines of determined genotype. Findings were replicated in
a separate set of pre-genotyped samples with equivalent results.
Transport activities were analyzed by a One-Way ANOVA with post-
hoc Dunnett’s tests, with p<0.05(*) taken as significant. C) 5-HT
transport activity of autism-associated SERT coding variants in
transfected HeLa cells. All variants were transfected in parallel with
reference hSERT cDNA into HeLa cells and assayed for 5-HT
transport activity. Data reflect mean values±SEM of 3 separate
experiments. Means were compared to hSERT cDNA using a One-
Way ANOVA followed by Dunnett’s test of individual means against
hSERT values with p<0.05(*) taken as significant. Figure reproduced
from authors’ prior work [79]
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Fig. 2 Analysis of protein expression of autism-associated SERT
coding variants. Impact of SERT coding variants on total and cell
surface [
125I]RTI-55 binding. HeLa cells transiently transfected with
hSERT or one of the SERT coding variants were subjected to intact
cell binding assays at 4°C with the cocaine analog [
125I]RTI-55
(5 nM). A) Total binding values as defined with paroxetine (10µM) as
displacer. B) Surface labeling by [
125I]RTI-55 as defined with 5-HT
(100µM) as displacer. In vehicle-treated cells, hSERT total binding
(fmol/10
5) was 583.7±20.6, and the surface binding was 175.7±11.7.
Results for A) and B) reflect mean values±SEM of three separate
experiments normalized to hSERT (100%). Binding levels were
analyzed via a One-Way ANOVA followed by post-hoc Dunnett’s
tests comparing mutant means to hSERT, with p<0.05(*) taken as
significant. C) Immunoblots of total cell extracts prepared from HeLa
cells transfected with hSERT or one of the variants described in the
study. D) Cell surface expression alterations in hSERT Gly56Ala,
Ile425Leu, Phe465Leu and Leu550Val. Variants were transfected in
parallel with hSERT into HeLa cells and cell surface transporters
identified by immunoblotting of biotinylated samples. Quantitative
estimations of relative E) total and F) surface density of hSERT,
Gly56Ala, Ile425Leu, Phe465Leu and Leu550Val based on densitom-
etry of biotinylation immunoblots. Data reflect mean values of three
separate experiments±SEM. Means were compared with a One-Way
ANOVA followed by Dunnett’s test to compare variant surface
expression to that achieved with hSERT, with p<0.05 taken as
significant (* Significantly elevated vs hSERT, p<0.05; ⋕ Significant-
ly reduced vs hSERT, p<0.05). Figure reproduced from authors’ prior
work [79]
Table 1 Rare serotonin transporter coding variants identified in autism and autism spectrum (Jeremy)
SERT variant Location Effect on Function
Gly56Ala [49] N-terminal intracellular tail ~30% increase in 5-HT uptake; absent upregulation by PKG, p38-MAPK [72, 79]
Ile425Leu [49] Transmembrane domain ~70% increase in 5-HT uptake; increased cell surface expression [79]
Ile425Val [77] Transmembrane domain ~70% increase in 5-HT uptake; increased cell surface expression vs. altered
PKG regulation [79, 94]
Phe465Leu [49] Transmembrane domain ~70% increase in 5-HT uptake; increased cell surface expression [79]
Leu550Val [49] Transmembrane domain ~70% increase in 5-HT uptake; increased cell surface expression [79]
Lys605Asn [49] C-terminal intracellular tail ~30% increase in 5-HT uptake [72]
J Neurodevelop Disord (2009) 1:158–171 163phosphorylation relevant to PP2A action, further clarifying
the mechanism of loss of PP2A sensitivity.
The studies reviewed above for altered SERT regulation
in autism-associated coding variants derive from
transiently-transfected cells. In an attempt to generate a
stable model for SERT variants, where expression is driven
from the same genomic locus, we produced stable cell lines
with the wildtype SERT, Ala56 and Leu425 using the
CHO-Flp-In model. Surprisingly, 5-HT transport assays and
Western blots of CHO cell extracts revealed a significant
reduction in SERT activity and expression for both SERT
Ala56Ala and Leu425 compared to hSERT (Fig. 4). Our
current hypothesis for this effect is that it is a result of
growth suppression and cell death that arises with elevated
5-HT accumulation in cells that do not have a vesicular
storage compartment for the amine. Although this finding
may appear to be a symptom of heterologous expression, we
recognize that SERT is expressed in contexts without such
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Fig. 3 Impact of 8BrcGMP and p38 MAPK on SERT activity of
autism-associated hSERT coding variants. A) Activity modulation.
HeLa cells transfected with hSERT or autism-associated hSERT
coding variants were examined for 5-HT transport activities following
pretreatments of cells with either 100µM 8BrcGMP or vehicle for
1 hr. Parallel wells were treated with the PKG inhibitor H8 (10µM) to
validate specificity. B) Altered p38 MAPK-dependent regulation of
hSERT in transfected HeLa cells. Cells transfected with hSERT or
autism-associated hSERT coding variants were examined for 5-HT
transport activities following pretreatments of cells with either 1µM
anisomycin or vehicle for 10 min. Parallel wells were treated with the
p38 MAPK inhibitor SB203580 (1µM) to validate specificity. Results
reflect mean values±SEM of three separate experiments normalized to
each mutant’s control measured under vehicle treated conditions
(100%). Results in A and B reflect mean values ± SEM of three
separate experiments normalized to each mutant’s level under vehicle
treated conditions (100%). Data were analyzed by a One-Way
ANOVA with post-hoc Bonferonni tests comparing variant to hSERT
8BrcGMP/anisomycin responses with p<0.05 taken as significant.
Figure reproduced from authors’ prior work [79]
164 J Neurodevelop Disord (2009) 1:158–171vesicular compartments, raising the possibility that alter-
ations in cell growth and viability arise as a consequence of
heightened SERT expression and contribute in unexpected
ways to the complex phenotypes observed in autism. Despite
these basal effects on expression, we were able to use this
model to investigate changes in catalytic rates. In the CHO-
Flp-In model, when functional activity is normalized by
surface expression, a significant catalytic activation is
evident for both Gly56Ala and Ile425Leu. Together, these
findings suggest that heterologous expression systems
provide important, but likely only partial windows on the
impact of autism-associated SERT variants.
Ideally, one would like to evaluate the impact of SERT
coding variants on the brain of autism subjects. While we
hope to pursue this need with transgenic mice, it seems
unlikely that such analyses in humans will be available in
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Fig. 4 Altered activity of SERT variants is differently exhibited in
CHO-Flip-In™ stable cells. A) 5-HT transport activity of autism-
associated SERT coding variants in CHO-Flip-In™ stable cells. All
variants were assayed for 5-HT transport activity. Data reflect mean
values±SEM of 3 separate experiments. Means for variants were
compared to hSERT using a One-Way ANOVA followed by Dunnett’s
test of individual means against hSERT values with p<0.05(*) taken
as significant. B) Immunoblots of total cell extracts prepared from
CHO-Flip-In™ stable cells expressing hSERT or one of the variants
described in the study. C) Cell surface expression alterations in
hSERT, Gly56Ala, and Ile425Leu. Cell surface transporters were
identified by immunoblotting of biotinylated samples. Quantitative
estimations of relative D) total and E) surface density of hSERT,
Gly56Ala, and Ile425Leu based on densitometry of biotinylation
immunoblots. Data reflect mean values of three separate experiments±
SEM. Means were compared with a One-Way ANOVA followed by
Dunnett’s test to compare variant surface expression to that achieved
with hSERT, with p<.05 taken as significant. F) Gly56Ala and
Ile425leu proteins exhibit enhanced catalytic function, with a turnover
rate of ~250% or more than that of wildtype SERT. Data reflect mean
values of three separate experiments±SEM. Means were compared
with a One-Way ANOVA followed by Dunnett’st e s t .F i g u r e
reproduced from authors’ prior work [79]
J Neurodevelop Disord (2009) 1:158–171 165the near future. It is well known, however, that SERT is
expressed in transformed lymphoblasts [52], the very same
models used to archive DNA from subjects recruited for
genetic studies. We took advantage of this opportunity to
examine basal transport activity and regulation in cells
derived from autism subjects. Indeed, Ala56 [79], as well as
the other autism-associated SERT variants, display elevated
5-HT transport activity (Fig. 1). As a control in the latter
studies, L-glutamate transport was found to be equivalent to
that in wildtype SERT, consistent with alterations derived
from a specific influence on SERT expression and/or
regulation. Interestingly, although transformed lympho-
blasts do not express a vesicular storage mechanism for 5-
HT (to our knowledge), SERT expression is low in these
cells relative to platelet and raphe neurons, such that the
growth perturbations noted above for stable CHO-Flp-In
cells do not appear to reduce our ability to detect 5-HT
transport enhancement. Studies with multiple lymphoblast
lines expressing the Ala56 variant [49] also reveal that
activators of PKG and p38 MAPK display the loss of
kinase sensitivity seen with transfected HeLa cells. Togeth-
er, these findings reinforce the properties of autism-
associated SERT variants as gain-of-function mutants that
also display complex regulatory deficits.
In vivo manipulations of the mouse SERT gene
A number of methods are available to manipulate genes in
the mouse, including gene knockout, regional or inducible
gene knockout, and transgenic overexpression, including
inducible and reversible systems. The first knockout of the
mouse SERT gene was performed by deletion of exon 2 in
the labs of Dennis Murphy and Klaus-Peter Lesch [82].
Over two hundred papers have now been published
describing this mouse’s phenotype, which includes in-
creased anxiety-like behavior, increased stress reactivity,
decreased aggression, obesity, and disruption of brain
architecture in the sensory cortex and amygdala (reviewed
in [51]). Despite seeing decreased platelet 5-HT levels, the
opposite of what is observed in the hyperserotonemia of
autism, these mice also show decreased sociability in the
Crawley test [83]. Interestingly, when bred with mice
haploinsufficient for Pten, a putative autism susceptibility
gene, SERT +/− knockout mice show an exacerbation of
the macrocephaly and decreased sociability characteristic of
the Pten +/− mice [68]. These findings may be consistent
with the idea that SERT activity may be constrained within
a certain range, with elevated or diminished SERT function
leading to vulnerability to autism-like behavior.
Another genetic manipulation was performed in a mouse
line expressing a human SERT transgene generated in the
lab of Trevor Sharp [84]. These mice show a 2- to 3-fold
increase in SERT binding sites and a resulting decrease in
extracellular 5-HT. Their platelet 5-HT levels have not yet
been assessed. Providing a contrast to the SERT knockout
mice, these hSERT transgenic overexpressing mice show a
decrease in anxiety-like behavior that reverses with acute
treatment with a 5-HT reuptake inhibitor. Furthermore, they
show increased sensitivity to 5-HT2 receptor stimulation
[85], again in contrast to the SERT KO mice, which show
decreased sensitivity [86]. This mouse could potentially
serve as a surrogate model of the increased SERT function
hypothesized in autism and OCD, but the use of a human
SERT locus introduced using a yeast artificial chromosome
construct may lead to alterations in gene regulation and
expression patterns, as well as altered protein regulation
and function, when introduced into the mouse.
Based upon our belief that manipulation of a native gene
was likely to yield a meaningful brain and behavioral read-
out of increased SERT function, we chose to introduce a
knock-in of the Ala56 allele into the native mouse SERT
gene. We chose the Ala56 allele for three reasons: 1) it
shows association with rigid-compulsive behavior and
sensory aversion in autism; 2) it is the most common
amino acid variant of human SERT; 3) it offers an
opportunity to probe the importance of altered SERT
regulation in vivo.
Methods
Production of mSERT Gly56Ala knock-in mouse
Approval was obtained from the Vanderbilt Institutional
Animal Care and Use Committee for all experiments
involving mice. A targeting construct was created contain-
ing exons 2–5 of the mouse 129S6 Slc6a4 gene with a
floxed Neomycin-resistance cassette inserted between
exons 4 and 5 (SERT Ala56-Neo, Fig. 5). This construct
was electroporated into mouse 129S6 embryonic stem cells
in the Vanderbilt University Transgenic Mouse / Embryonic
Stem Cell Shared Resource facility. Correct targeting of the
Ala56-Neo knock-in allele was identified by polymerase
chain reaction screening (PCR) and confirmed by Southern
blot. Embryonic stem cells containing the SERTAla56-Neo
knock-in allele were then microinjected into the blastocoel
cavity of 3.5-day-old C57Bl/6 embryos, which were then
transferred into the uterus of a pseudopregnant recipient
animal. The resulting chimeric animals were bred with
129S6 female mice. Pups were screened by PCR for
germline transmission of the SERT Ala56-Neo allele.
Heterozygous Gly56Ala-Neo animals were then bred to a
129S4 protamine-Cre mouse line to allow germline
excision of the SERT-56Ala-Neo floxed Neomycin-
resistance cassette [87]. The resulting SERT Gly56Ala
pups were bred to generate a colony of mice including
166 J Neurodevelop Disord (2009) 1:158–171Ala/Ala knock-in mice and wildtype Gly/Gly littermate
controls.
Genotyping and initial growth analysis of SERT Ala56
knock-in mice
At two weeks of age, a 3–5 mm section of tail was removed
for DNA extraction using the Sigma REDExtract-N-Amp
Tissue PCR Kit (Sigma-Aldrich, St. Louis, MO, http://
www.sigmaaldrich.com). Each PCR reaction contained
2μL of tail DNA extract, 5μL of Sigma REDExtract-N-
Amp PCR Reaction Mix, 0.5μL of each of the two 25-μM
primers (Sense 5′-cctggccctcttagcaggtt-3′; Antisense 5′-
aggaggagaagccagcaagg-3′), and 2μL of water, for a 10-μL
total reaction volume. All of the PCR reactions were
performed on an MJ Research DNA Engine PTC-200
thermocycler (Bio-Rad, Hercules, CA, http://www.bio-rad.
com) under the following conditions: initial denaturation
step of 94° C for 2 min; followed by 5 cycles of three
alternating steps (94° C for 30 sec, 63° C for 45 sec, and
7 2 °Cf o r6 0s e c ) ;f o l l o w e db y3 5c y c l e so ft h r e e
alternating steps (94° C for 30 sec, 61° C for 45 sec, and
72° C for 60 sec); followed by one final extension step of
72° C for 8 min. Final PCR products were analyzed by
horizontal gel electrophoresis in 1% agarose (GenePure LE,
ISC BioExpress, Kaysville, UT, http://www.bioexpress.
com). The PCR product from the wildtype 129S6 SERT
gene allele is 642 bp long, and the PCR product from the
mutant 129S6 SERT Ala56 allele is 752 bp long. The χ
2
test was used to evaluate deviation from expected Hardy-
Weinberg equilibrium allele frequencies.
Pups from SERT 56Gly/Ala heterozygote matings were
weighed weekly from one week of age until eight weeks of
age. Repeated Measures Analysis of Variance was used to
evaluate sources of variation between mice of different
genotypes over time.
Results and discussion
We have successfully introduced the SERTAla56 allele into
a 129S6 mouse background. Out of 308 embryonic stem
cell lines that survived neomycin selection, a single ES line
positive for the knock-in allele was selected for transfer to
pseudopregnant females and chimera production. Eight
chimeras with significant evidence of mosaicism were
generated and animals with the greatest degree of 129S6
DNA, as assessed by coat color, were selected to analyze
germ-line transmission, generating our founder animal and
subsequent progeny. We then used Cre-based recombina-
tion to remove the neomycin-resistance cassette that often
interferes with targeted gene expression. Heterozygous
animals were bred to homozygosity on a 129S6 background
and maintained this way except for initiation of back-
crossing to C57BL/6J (ongoing). The initial 129S6 SERT
Ala56 mice are viable and show a normal distribution of
Fig. 5 Diagram for Knock-in of
Gly56Ala allele in to Slc6a4
locus. The targeting vector with
the Ala56 knock-in mutation
contained a floxed positive
selection Neomycin-resistance
cassette and a negative selection
thymidine kinase cassette.
Recombination with 129S6 em-
bryonic stem cell DNA resulted
in an Slc6a4 gene containing the
Ala56 knock-in mutation, as
well as two loxP sites surround-
ing the Neomycin-resistance
cassette in intron 4. Breeding
with Protamine (Prm) Cre
transgenic mice yielded excision
of the floxed Neomycin-
resistance cassette with retention
of a residual loxP site in intron 4
J Neurodevelop Disord (2009) 1:158–171 167genotypes in their offspring (Table 2) (Test for deviation
from Hardy-Weinberg equilibrium χ
2=0.14, p=0.93). Their
initial growth trajectory mirrors that of the wildtype animals
(Repeated Measures ANOVA, Genotype F=0.44, p=0.65;
Interaction F=0.46, p=0.95) (Fig. 6).
With the successful generation of both homozygous
Ala/Ala mice as well as heterozygous carriers, our thoughts
now turn to analyses that are predicted by trait associations
in children possessing the variant, as well as biochemical
and behavioral traits seen in autism more generally.
Modeling the SERT Ala56 variant in transfected cells and
in transformed cells has identified an intriguing phenotype
of increased baseline activity and failure to further
upregulate via the PKG and p38-MAPK pathways. In vivo
modeling of this variant in a knock-in mouse will allow us
to answer a number of questions, ranging from basic to
translational. We will need to verify that mRNA and protein
expression patterns resulting from the introduction of this
knock-in allele will parallel native mouse SERT. We will
want to establish that the SERT Ala56 in vitro phenotype of
increased transport is recapitulated in the mouse, initially
using synaptosome preparations or platelets and progress-
ing to in vivo assays. We will also evaluate whether the
biomarker of elevated platelet 5-HT is present in the SERT
Ala56 mouse.
After initial studies establish the characteristics of the
mouse SERT Ala56 variant in vivo, a number of intriguing
questions await. Some of these questions correspond to
establishing face validity for behavioral traits that map onto
autism symptoms (reviewed in [88]). Will the SERT Ala56
mice show alterations in social behavior [89]? Will they
show repetitive behavior, perseverative exploration, or
deficits in reversal learning, paralleling the association of
SERT Ala56 with rigid-compulsive behavior [90]? Will
they show increased sensory sensitivity, paralleling the
association with sensory aversion [91]? Other questions
relate to predicted behavioral changes due to altered SERT
function. Will SERT Ala56 mice show altered response to
pharmacological probes of the 5-HT system, including 5-
HT reuptake inhibitors and 5-HT receptor agonists? Might
these mice help resolve the conundrum of replicated
reductions in 5HT2 receptor density but utility of the
5HT2a antagonist risperidone? Will they demonstrate
changes in anxiety or stress reactivity that contrast with
the SERT knockout mouse [51]?
Our efforts to establish a behavioral readout of altered
SERT function will rest on an understanding of underlying
changes in brain development, synaptic function and
signaling. Indeed, we believe this can help address the
impact of SERT variation on brain architecture. Our initial
focus will be targeted to brain regions that are altered in the
SERT knockout mouse [91, 92] and/or those regions that
may act as substrates for the behavioral alterations found in
individuals with the SERT Ala56 variant. We then hope to
advance from any observed changes in brain architecture to
elucidate the underlying alterations in neurodevelopment
that lead to these changes. Ultimately, our hope would be
not just to characterize a brain and behavioral phenotype in
the SERT Ala56 knock-in mouse, but also to capitalize on
the model to develop novel methods of reversing the
phenotype, either genetically or pharmacologically.
We have entered a new era in autism research with the
transfer to animal models of functional human mutations
linked to autism symptom domains. Time will tell if our
efforts help unravel the complexities of autism, including
the well known male bias, the long-standing biomarker of
hyperserotonemia, and the seemingly independent trait
domains that have been suggested to arise from distinct
genetic mechanisms [93]. We have optimism that success in
this venture can advance critical new models for the design
of gene- or biomarker-based therapeutics.
Acknowledgements We gratefully acknowledge the input and
support of Ana Carneiro, Chong-Bin Zhu, David Airey and
investigators/staff of the Vanderbilt Silvio O. Conte Center for
Neuroscience Research. We also appreciate the expert laboratory
oversight provided by Jane Wright, Qiao Han, Angela Steele, Sarah
Whitaker, and Kathryn Lindler. Research efforts were supported by
Fig. 6 Growth curves for wildtype and Ala56/Ala mice. Weight was
recorded weekly from one week to eight weeks of life. Male growth is
shown. Repeated measures ANOVA revealed a significant effect of
week (F=996, p<0.001) but no significant effects of genotype (F=
0.44, p=0.65) or genotype x week interaction (F=0.47, p=0.95).
Female growth also did not differ between genotypes (data not shown)
Table 2 Genotype distribution of Gly56Ala offspring from heterozy-
gous breeding pairs
Gly/Gly Gly/Ala Ala/Ala
Pups from 56Gly/Ala breeding 18 (20
∙) 42 (41
∙) 21 (20
∙)
∙expectation from Hardy-Weinberg equilibrium
168 J Neurodevelop Disord (2009) 1:158–171NIH Award K08MH081066, an American Academy of Child and
Adolescent Psychiatry Pilot Research Award and an Autism Speaks
Pilot Award to J.V., a Scientist-Educator Award to B.J.T, a NARSAD
Young Investigator Award to H.C.P. and NIH Awards NS049261 to J.S.
S., DA07390 and MH078028 to R.D.B., and HD15052 for support of
the Vanderbilt Transgenic Mouse/ESC Shared Resource.
References
1. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabo-
lism in autistic and other mentally retarded children. J Pediatr.
1961;58:315–20.
2. Folk GE Jr, Long JP. Serotonin as a neurotransmitter: a review.
Comp Biochem Physiol C. 1988;91:251–7.
3. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin;
isolation and characterization. J Biol Chem. 1948;176:1243–51.
4. Erspamer V, Asero B. Identification of enteramine, the specific
hormone of the enterochromaffin cell system, as 5-
hydroxytryptamine. Nature. 1952;169:800–1.
5. Anderson GM, Feibel FC, Cohen DJ. Determination of serotonin
in whole blood, platelet-rich plasma, platelet-poor plasma and
plasma ultrafiltrate. Life Sci. 1987;40:1063–70.
6. Cook EH, Leventhal BL, Freedman DX. Free serotonin in plasma:
Autistic children and their first-degree relatives. Biol Psychiatry.
1988;24:488–91.
7. Spivak B, Golubchik P, Mozes T, Vered Y, Nechmad A, Weizman
A, et al. Low platelet-poor plasma levels of serotonin in adult
autistic patients. Neuropsychobiology. 2004;50:157–60.
8. Kanner L. Autistic disturbances of affective contact. Nerv Child.
1943;2:217–50.
9. Cook E, Leventhal B. The serotonin system in autism. Curr Opin
Pediatr. 1996;8:348–54.
10. Mulder EJ, Anderson GM, Kema IP, de Bildt A, van Lang ND,
den Boer JA, et al. Platelet serotonin levels in pervasive
developmental disorders and mental retardation: diagnostic group
differences, within-group distribution, and behavioral correlates. J
Am Acad Child Adolesc Psychiatry. 2004;43:491–9.
11. Cook E, Arora R, Anderson G, Berry-Kravis E, Yan S-Y, Yeoh H,
et al. Platelet serotonin studies in hyperserotonemic relatives of
children with autistic disorder. Life Sci. 1993;52:2005–15.
12. Marazziti D, Muratori F, Cesari A, Masala I, Baroni S,
Giannaccini G, et al. Increased density of the platelet serotonin
transporter in autism. Pharmacopsychiatry. 2000;33:165–8.
13. Bursztejn C, Ferrari P, Dreux C, Braconnier A, Lancrenon S.
Metabolisme de la serotonine dans l'autisme infantile. Encephalé.
1988;14:413–9.
14. Katsui T, Okuda M, Usuda S, Koizumi T. Kinetics of 3H-
serotonin uptake by platelets in infantile autism and developmen-
tal language disorder (including five pairs of twins). J Autism Dev
Disord. 1986;16:69–76.
15. Anderson GM, Minderaa RB, van Benthem PP, Volkmar FR,
Cohen DJ. Platelet imipramine binding in autistic subjects.
Psychiatry Res. 1984;11:133–41.
16. Rotman A, Caplan R, Szekely GA. Platelet uptake of serotonin in
psychotic children. Psychopharmacology (Berl). 1980;67:245–8.
17. Sankar DVS. Uptake of 5-hydroxytryptamine by isolated platelets
in childhood schizophrenia and autism. Neuropsychobiology.
1977;3:234–9.
18. Yuwiler A, Ritvo E, Geller E, Glousman R, Schneiderman G,
Matsuno D. Uptake and efflux of serotonin from platelets of autistic
and nonautistic children. J Autism Dev Disord. 1975;5:83–98.
19. Hranilovic D, Bujas-Petkovic Z, Tomicic M, Bordukalo-Niksic T,
Blazevic S, Cicin-Sain L. Hyperserotonemia in autism: activity of
5HT-associated platelet proteins. J Neural Transm .2009
20. Cook EH Jr, Arora RC, Anderson GM, Berry-Kravis EM, Yan SY,
Yeoh HC, et al. Platelet serotonin studies in hyperserotonemic
relatives of children with autistic disorder. Life Sci.
1993;52:2005–15.
21. Perry BD, Cook EH Jr, Leventhal BL, Wainwright MS, Freedman
DX. Platelet 5-HT2 serotonin receptor binding sites in autistic
children and their first-degree relatives. Biol Psychiatry.
1991;30:121–30.
22. McBride PA, Anderson GM, Hertzig ME, Sweeney JA, Kream J,
Cohen DJ, et al. Serotonergic responsivity in male young adults
with autistic disorder. Arch Gen Psychiatry. 1989;46:205–12.
23. Carneiro AM, Blakely RD. Serotonin, protein kinase C and HIC-5
associated redistribution of the platelet serotonin transporter. J
Biol Chem. 2006.
24. Steiner JA, Carneiro AM, Blakely RD. Going with the flow:
trafficking-dependent and -independent regulation of serotonin
transport. Traffic. 2008;9:1393–402.
25. Carneiro AM, Blakely RD. Serotonin-, protein kinase C-, and Hic-
5-associated redistribution of the platelet serotonin transporter. J
Biol Chem. 2006;281:24769–80.
26. Carneiro AM, Cook EH, Murphy DL, Blakely RD. Interactions
between integrin alphaIIbbeta3 and the serotonin transporter
regulate serotonin transport and platelet aggregation in mice and
humans. J Clin Invest. 2008;118:1544–52.
27. Janusonis S, Anderson GM, Shifrovich I, Rakic P. Ontogeny of
brain and blood serotonin levels in 5-HT receptor knockout mice:
potential relevance to the neurobiology of autism. J Neurochem.
2006;99:1019–31.
28. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G,
et al. Lrp5 controls bone formation by inhibiting serotonin
synthesis in the duodenum. Cell. 2008;135:825–37.
29. Piven J, Tsai G, Nehme E, Coyle JT, Folstein SE. Platelet
serotonin, a possible marker for familial autism. J Autism Dev
Disord. 1991;21:51–9.
30. Abney M, McPeek MS, Ober C. Broad and narrow heritabilities
of quantitative traits in a founder population. Am J Hum Genet.
2001;68:1302–7.
31. Meltzer HY, Arora RC. Genetic control of serotonin uptake in
blood platelets: a twin study. Psychiatry Res. 1988;24:263–9.
32. Weiss LA, Veenstra-VanderWeele J, Abney M, Newman DL, Kim
S-J, Dytch H, McPeek MS, Cheng S, Cook EH, Jr., Ober C.
Genome-wide association study identifies ITGB3 as a QTL for
whole blood serotonin. European Journal of Human Genetics
2004;advance online publication.
33. Weiss LA, Abney M, Cook EH Jr, Ober C. Sex-specific genetic
architecture of whole blood serotonin levels. Am J Hum Genet.
2005;76:33–41.
34. Weiss LA, Ober C, Cook EH Jr. ITGB3 shows genetic and
expression interaction with SLC6A4. Hum Genet. 2006;120:93–
100.
35. Coutinho AM, Sousa I, Martins M, Correia C, Morgadinho T,
Bento C, et al. Evidence for epistasis between SLC6A4 and
ITGB3 in autism etiology and in the determination of platelet
serotonin levels. Hum Genet. 2007;121:243–56.
36. Mei H, Cuccaro ML, Martin ER. Multifactor dimensionality
reduction-phenomics: a novel method to capture genetic hetero-
geneity with use of phenotypic variables. Am J Hum Genet.
2007;81:1251–61.
37. Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee
J, et al. Developmental changes in brain serotonin synthesis
capacity in autistic and nonautistic children. Ann Neurol.
1999;45:287–95.
38. Murphy DG, Daly E, Schmitz N, Toal F, Murphy K, Curran S, et
al. Cortical serotonin 5-HT2A receptor binding and social
communication in adults with Asperger's syndrome: an in vivo
SPECT study. Am J Psychiatry. 2006;163:934–6.
J Neurodevelop Disord (2009) 1:158–171 16939. Goldberg J, Anderson GM, Zwaigenbaum L, Hall GB, Nahmias
C, Thompson A, et al. Cortical serotonin type-2 receptor density
in parents of children with autism spectrum disorders. J Autism
Dev Disord. 2009;39:97–104.
40. Antzoulatos E, Gibbs T, Pugh J, Bauman M, Kemper T, Blatt G.
Serotonin receptors in the autistic brain. In: Int Mtg for Autism
Res: Boston; 2005 p. P1A.2.1.
41. McDougle C, Naylor S, Cohen D, Aghajanian G, Heninger G,
Price L. Effects of tryptophan depletion in drug-free adults with
autistic disorder. Arch Gen Psychiatry. 1996;53:993–1000.
42. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S,
Wasserman S, et al. A placebo controlled crossover trial of liquid
fluoxetine on repetitive behaviors in childhood and adolescent
autism. Neuropsychopharmacology. 2005;30:582–9.
43. Gordon C, State R, Nelson J, Hamburger S, Rapoport J. A double-
blind comparison of clomipramine, desipramine, and placebo in
the treatment of autistic disorder. Arch Gen Psychiatry.
1993;50:441–7.
44. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman
MG, et al. Risperidone in children with autism and serious
behavioral problems. N Engl J Med. 2002;347:314–21.
45. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E,
Davies M, et al. Risperidone for the core symptom domains of
autism: results from the study by the autism network of the
research units on pediatric psychopharmacology. Am J Psychiatry.
2005;162:1142–8.
46. International Molecular Genetic Study of Autism Consortium. A
genome wide screen for autism: Strong evidence for linkage to
chromosomes 2q, 7q and 16p. Am J Hum Genet. 2001;69:570–81.
47. Yonan AL, Alarcon M, Cheng R, Magnusson PK, Spence SJ,
Palmer AA, et al. A genomewide screen of 345 families for
autism-susceptibility loci. Am J Hum Genet. 2003;73:886–97.
48. Stone JL, Merriman B, Cantor RM, Yonan AL, Gilliam TC,
Geschwind DH, et al. Evidence for sex-specific risk alleles in
autism spectrum disorder. Am J Hum Genet. 2004;75:1117–23.
49. Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q,
Jiang L, et al. Allelic Heterogeneity at the Serotonin Transporter
Locus (SLC6A4) Confers Susceptibility to Autism and Rigid-
Compulsive Behaviors. Am J Hum Genet. 2005;77:265–79.
50. Cantor RM, Kono N, Duvall JA, Alvarez-Retuerto A, Stone JL,
Alarcon M, Nelson SF, Geschwind DH. Replication of Autism
Linkage: Fine-Mapping Peak at 17q21. Am J Hum Genet.
2005;76.
51. Murphy DL, Lesch KP. Targeting the murine serotonin transport-
er: insights into human neurobiology. Nat Rev Neurosci.
2008;9:85–96.
52. Lesch K-P, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S,
et al. Association of anxiety-related traits with a polymorphism in
the serotonin transporter gene regulatory region. Science.
1996;274:1527–31.
53. Cook EH Jr, Courchesne R, Lord C, Cox NJ, Yan S, Lincoln A, et
al. Evidence of linkage between the serotonin transporter and
autistic disorder. Mol Psychiatry. 1997;2:247–50.
54. Huang CH, Santangelo SL. Autism and serotonin transporter gene
polymorphisms: a systematic review and meta-analysis. Am J
Med Genet B Neuropsychiatr Genet. 2008;147B:903–13.
55. Yonan AL, Palmer AA, Gilliam TC. Hardy-Weinberg disequilib-
rium identified genotyping error of the serotonin transporter
(SLC6A4) promoter polymorphism. Psychiatr Genet.
2006;16:31–4.
56. Wendland JR, Moya PR, Kruse MR, Ren-Patterson RF, Jensen
CL, Timpano KR, et al. A novel, putative gain-of-function
haplotype at SLC6A4 associates with obsessive-compulsive
disorder. Hum Mol Genet. 2008;17:717–23.
57. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg
BD, et al. Serotonin transporter promoter gain-of-function
genotypes are linked to obsessive-compulsive disorder. Am J
Hum Genet. 2006;78:815–26.
58. MacKenzie A, Quinn J. A serotonin transporter gene intron 2
polymorphic region, correlated with affective disorders, has allele-
dependent differential enhancer- like properties in the mouse
embryo. Proc Natl Acad Sci U S A. 1999;96:15251–5.
59. Kim S-J, Cox N, Courchesne R, Lord C, Corsello C, Akshoomoff
N, et al. Transmission disequilibrium mapping in the serotonin
transporter gene (SLC6A4) region in autistic disorder. Mol
Psychiatry. 2002;7:278–88.
60. McCauley JL, Olson LM, Dowd M, Amin T, Steele A, Blakely
RD, et al. Linkage and association analysis at the serotonin
transporter (SLC6A4) locus in a rigid-compulsive subset of
autism. Am J Med Genet B Neuropsychiatr Genet.
2004;127:104–12.
61. Cross S, Kim SJ, Weiss LA, Delahanty RJ, Sutcliffe JS, Leventhal
BL, et al. Molecular genetics of the platelet serotonin system in
first-degree relatives of patients with autism. Neuropsychophar-
macology. 2008;33:353–60.
62. Mulder EJ, Anderson GM, Kema IP, Brugman AM, Ketelaars CE,
de Bildt A, van Lang ND, den Boer JA, Minderaa RB. Serotonin
transporter intron 2 polymorphism associated with rigid-
compulsive behaviors in Dutch individuals with pervasive
developmental disorder. Am J Med Genet B Neuropsychiatr
Genet. 2005.
63. Brune CW, Kim SJ, Salt J, Leventhal BL, Lord C, Cook EH Jr. 5-
HTTLPR Genotype-Specific Phenotype in Children and Adoles-
cents With Autism. Am J Psychiatry. 2006;163:2148–56.
64. Coutinho AM, Oliveira G, Morgadinho T, Fesel C, Macedo TR,
Bento C, et al. Variants of the serotonin transporter gene
(SLC6A4) significantly contribute to hyperserotonemia in autism.
Mol Psychiatry. 2004;9:264–71.
65. Wassink TH, Hazlett HC, Epping EA, Arndt S, Dager SR,
Schellenberg GD, et al. Cerebral cortical gray matter overgrowth
and functional variation of the serotonin transporter gene in
autism. Arch Gen Psychiatry. 2007;64:709–17.
66. Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M,
Hollanders K, et al. Duplication of the MECP2 region is a
frequent cause of severe mental retardation and progressive
neurological symptoms in males. Am J Hum Genet.
2005;77:442–53.
67. Dickel DE, Veenstra-VanderWeele J, Bivens NC, Wu X, Fischer
DJ, Van Etten-Lee M, et al. Association studies of serotonin
system candidate genes in early-onset obsessive-compulsive
disorder. Biol Psychiatry. 2007;61:322–9.
68. Page DT, Kuti OJ, Prestia C, Sur M. Haploinsufficiency for Pten
and Serotonin transporter cooperatively influences brain size and
social behavior. Proc Natl Acad Sci U S A. 2009;106:1989–94.
69. Haase J, Killian AM, Magnani F, Williams C. Regulation of the
serotonin transporter by interacting proteins. Biochem Soc Trans.
2001;29:722–8.
70. Carneiro A, Ingram SL, Beaulieu J-M, Sweeney A, Amara SG,
Thomas SM, et al. The multiple LIM domain-containing adaptor
protein Hic-5 synaptically colocalizes and interacts with the
dopamine transporter. J Neurosci. 2002;22:7045–54.
71. Carneiro AM, Blakely RD. Serotonin, protein kinase C and HIC-5
associated redistribution of the platelet serotonin transporter. J
Biol Chem 2006;published online June 27.
72. Prasad HC, Zhu CB, McCauley JL, Samuvel DJ, Ramamoorthy
S, Shelton RC, et al. Human serotonin transporter variants
display altered sensitivity to protein kinase G and p38 mitogen-
activated protein kinase. Proc Natl Acad Sci U S A.
2005;102:11545–50.
73. Sakurai T, Reichert J, Hoffman EJ, Cai G, Jones HB, Faham M, et
al. A large-scale screen for coding variants in SERT/SLC6A4 in
autism spectrum disorders. Autism Res. 2008;1:251–7.
170 J Neurodevelop Disord (2009) 1:158–17174. Wendland JR, Kruse MR, Murphy DL. Functional SLITRK1
var321, varCDfs and SLC6A4 G56A variants and susceptibility to
obsessive-compulsive disorder. Mol Psychiatry. 2006;11:802–4.
75. Glatt C, DeYoung J, Delgado S, Service S, Giacomini K, Edwards
R, et al. Screening a large reference sample to identify very low
frequency sequence variants: comparisons between two genes.
Nat Genet. 2001;27:435–8.
76. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T,
Chang AS, et al. Antidepressant- and cocaine-sensitive human
serotonin transporter: molecular cloning, expression, and chromo-
somal localization. Proc Natl Acad Sci U S A. 1993;90:2542–6.
77. Ozaki N, Goldman D, Kaye W, Plotnikov K, Greenberg B,
Rudnick G, et al. A missense mutation in the serotonin transporter
is associated with a complex neuropsychiatric phenotype. Mol
Psychiatry. 2003;8:933–6.
78. Delorme R, Betancur C, Wagner M, Krebs MO, Gorwood P, Pearl
P, Nygren G, Durand CM, Buhtz F, Pickering P, Melke J,
Ruhrmann S, Anckarsater H, Chabane N, Kipman A, Reck C,
Millet B, Roy I, Mouren-Simeoni MC, Maier W, Rastam M,
Gillberg C, Leboyer M, Bourgeron T. Support for the association
between the rare functional variant I425V of the serotonin
transporter gene and susceptibility to obsessive compulsive
disorder. Mol Psychiatry. 2005.
79. Prasad HC, Steiner JA, Sutcliffe JS, Blakely RD. Enhanced
activity of human serotonin transporter variants associated with
autism. Philos Trans R Soc Lond B Biol Sci. 2009;364:163–73.
80. Zhu CB, Hewlett WA, Feoktistov I, Biaggioni I, Blakely RD.
Adenosine receptor, protein kinase G, and p38 mitogen-activated
protein kinase-dependent up-regulation of serotonin transporters
involves both transporter trafficking and activation. Mol Pharma-
col. 2004;65:1462–74.
81. Bauman AL, Apparsundaram S, Ramamoorthy S, Wadzinski BE,
Vaughan RA, Blakely RD. Cocaine and antidepressant-sensitive
biogenic amine transporters exist in regulated complexes with
protein phosphatase 2A. J Neurosci. 2000;20:7571–8.
82. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D,
Heils A, et al. Altered brain serotonin homeostasis and locomotor
insensitivity to 3, 4- methylenedioxymethamphetamine (“Ecsta-
sy”) in serotonin transporter- deficient mice. Mol Pharmacol.
1998;53:649–55.
83. Moy SS, Nadler JJ, Young NB, Nonneman RJ, Grossman AW,
Murphy DL, D’Ercole AJ, Crawley JN, Magnuson TR, Lauder
JM. Social Approach in Genetically-Engineered Mouse Lines
Relevant to Autism. Genes Brain Behav. 2008.
84. Jennings KA, Loder MK, Sheward WJ, Pei Q, Deacon RM,
Benson MA, et al. Increased expression of the 5-HT transporter
confers a low-anxiety phenotype linked to decreased 5-HT
transmission. J Neurosci. 2006;26:8955–64.
85. Jennings KA, Sheward WJ, Harmar AJ, Sharp T. Evidence that
genetic variation in 5-HT transporter expression is linked to
changes in 5-HT2A receptor function. Neuropharmacology.
2008;54:776–83.
86. Qu Y, Villacreses N, Murphy DL, Rapoport SI. 5-HT2A/2C
receptor signaling via phospholipase A2 and arachidonic acid is
attenuated in mice lacking the serotonin reuptake transporter.
Psychopharmacology (Berl). 2005;180:12–20.
87. O’Gorman S, Dagenais NA, Qian M, Marchuk Y. Protamine-Cre
recombinase transgenes efficiently recombine target sequences in
the male germ line of mice, but not in embryonic stem cells. Proc
Natl Acad Sci U S A. 1997;94:14602–7.
88. Crawley JN. Mouse behavioral assays relevant to the symptoms of
autism. Brain Pathol. 2007;17:448–59.
89. Moy SS, Nadler JJ, Perez A, Barbaro RP, Johns JM, Magnuson
TR, et al. Sociability and preference for social novelty in five
inbred strains: an approach to assess autistic-like behavior in mice.
Genes Brain Behav. 2004;3:287–302.
90. Moy SS, Nadler JJ, Poe MD, Nonneman RJ, Young NB, Koller BH,
etal.Developmentofamousetestforrepetitive,restrictedbehaviors:
relevance to autism. Behav Brain Res. 2008;188:178–94.
91. Esaki T, Cook M, Shimoji K, Murphy DL, Sokoloff L, Holmes A.
Developmental disruption of serotonin transporter function
impairs cerebral responses to whisker stimulation in mice. Proc
Natl Acad Sci U S A. 2005;102:5582–7.
92. Wellman CL, Izquierdo A, Garrett JE, Martin KP, Carroll J,
Millstein R, et al. Impaired stress-coping and fear extinction and
abnormal corticolimbic morphology in serotonin transporter
knock-out mice. J Neurosci. 2007;27:684–91.
93. Hus V, Pickles A, Cook EH Jr, Risi S, Lord C. Using the autism
diagnostic interview–revised to increase phenotypic homogeneity
in genetic studies of autism. Biol Psychiatry. 2007;61:438–48.
94. Zhang YW, Gesmonde J, Ramamoorthy S, Rudnick G. Serotonin
transporter phosphorylation by cGMP-dependent protein kinase is
altered by a mutation associated with obsessive compulsive
disorder. J Neurosci. 2007;27:10878–86.
J Neurodevelop Disord (2009) 1:158–171 171